Evidence map›Paper›PMID 24004612›Full record

ArticleGenome medicine2013

Clinical and molecular characterization of HER2 amplified-pancreatic cancer.

Angela Chou, Nicola Waddell, Mark J Cowley, Anthony J Gill, David K Chang, Ann-Marie Patch, Katia Nones, Jianmin Wu, Mark Pinese, Amber L Johns and 18 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genome medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
72citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

72 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Article
  8. Improving outcomes of patients with pancreatic cancer.Nature reviews. Clinical oncology · 2025
    Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Frontiers in oncology · 2024
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

12 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors.

Angela ChouKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Anatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Nicola WaddellQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Mark J CowleyKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Anthony J GillKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Department of Anatomical Pathology, Royal North Shore Hospital, St Lenoards, Sydney, Australia ; Sydney Medical School, University of Sydney, Sydney, Australia.
David K ChangKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK ; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.
Ann-Marie PatchQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Katia NonesQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Jianmin WuKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Mark PineseKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Amber L JohnsKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
David K MillerQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Karin S KassahnQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Adnan M NagrialKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Harpreet WasanDepartment of Cancer Medicine, Hammersmith Hospital, Imperial College Healthcare NHS Trust, London, UK.
David GoldsteinPrince of Wales Clinical School, University of New South Wales and Prince of Wales Hospital, Sydney, Australia.
Christopher W ToonDepartment of Anatomical Pathology, Royal North Shore Hospital, St Lenoards, Sydney, Australia ; Sydney Medical School, University of Sydney, Sydney, Australia ; Histopath Pathology, 97 Waterloo Road, North Ryde, NSW 2113, Australia.
Venessa ChinKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Lorraine ChantrillKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia ; Macarthur Cancer Therapy Centre, Sydney South West District Health Service, Sydney, NSW, Australia.
Jeremy HumphrisKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia.
R Scott MeadKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Anatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Ilse RoomanKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Jaswinder S SamraUpper Gastrointestinal Surgery Unit, Royal North Shore Hospital, Sydney, Australia.
Marina PajicKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; St Vincent's Clinical School, University of New South Wales, Sydney, Australia.
Elizabeth A MusgroveKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
John V PearsonQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia.
Adrienne L MoreyAnatomical Pathology, Sydpath, St Vincent's Hospital, Sydney, Australia.
Sean M GrimmondQueensland Centre for Medical Genomics, Institute for Molecular Bioscience, University of Queensland, Brisbane, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK.
Andrew V BiankinKinghorn Cancer Centre and Garvan Institute of Medical Research, Darlinghurst, Sydney, Australia ; Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK ; West of Scotland Pancreatic Unit, Glasgow Royal Infirmary, Glasgow, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPancreatic cancer is one of the most lethal and molecularly diverse malignancies. Repurposing of therapeutics that target specific molecular mechanisms in different disease types offers potential for rapid improvements in outcome. Although HER2 amplification occurs in pancreatic cancer, it is inadequately characterized to exploit the potential of anti-HER2 therapies.

methodsHER2 amplification was detected and further analyzed using multiple genomic sequencing approaches. Standardized reference laboratory assays defined HER2 amplification in a large cohort of patients (n = 469) with pancreatic ductal adenocarcinoma (PDAC).

resultsAn amplified inversion event (1 MB) was identified at the HER2 locus in a patient with PDAC. Using standardized laboratory assays, we established diagnostic criteria for HER2 amplification in PDAC, and observed a prevalence of 2%. Clinically, HER2- amplified PDAC was characterized by a lack of liver metastases, and a preponderance of lung and brain metastases. Excluding breast and gastric cancer, the incidence of HER2-amplified cancers in the USA is >22,000 per annum.

conclusionsHER2 amplification occurs in 2% of PDAC, and has distinct features with implications for clinical practice. The molecular heterogeneity of PDAC implies that even an incidence of 2% represents an attractive target for anti-HER2 therapies, as options for PDAC are limited. Recruiting patients based on HER2 amplification, rather than organ of origin, could make trials of anti-HER2 therapies feasible in less common cancer types.

Identifiers

PMID24004612
PMCPMC3978667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.